Odyssey Mono

Effect of Alirocumab 75 mg Subcutaneously Every 2 Weeks as Monotherapy Versus Ezetimibe Over 24 Weeks

Eli M Roth; James M McKenney


Future Cardiol. 2015;11(1):27-37. 

In This Article


These data suggest that the 75-mg dose of alirocumab sc. Q2W may be appropriate for adequate lowering of LDL-C in a large portion of patients with primary hypercholesterolemia at moderate CV risk who are not receiving statin therapy. In addition, the safety profile continues to show good tolerability and appears comparable to that of ezetimibe in this study. Alirocumab self-injected sc. Q2W appears to be a viable option for lowering LDL-C in patients unable or unwilling to utilize statin therapy. An uptitration plan based on LDL-C response appears to be feasible and may be useful in future clinical practice. Alirocumab significantly lowers LDL-C to a much greater degree than ezetimibe, which is a commonly prescribed lipid-lowering medicine.